Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) had its price target upped by stock analysts at Royal Bank of Canada from $30.00 to $32.00 in a report released on Wednesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank of Canada’s price target indicates a potential upside of 76.02% from the stock’s previous close.
CTNM has been the subject of several other reports. Morgan Stanley assumed coverage on Contineum Therapeutics in a research note on Tuesday, April 30th. They set an “overweight” rating and a $25.00 target price for the company. Stifel Nicolaus started coverage on Contineum Therapeutics in a research note on Tuesday, April 30th. They set a “buy” rating and a $29.00 price objective for the company.
Check Out Our Latest Analysis on Contineum Therapeutics
Contineum Therapeutics Price Performance
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.02). On average, analysts anticipate that Contineum Therapeutics will post -1.95 EPS for the current fiscal year.
Institutional Investors Weigh In On Contineum Therapeutics
A number of institutional investors have recently modified their holdings of CTNM. Rhumbline Advisers bought a new position in shares of Contineum Therapeutics during the 2nd quarter worth about $118,000. Bank of New York Mellon Corp bought a new position in Contineum Therapeutics in the second quarter valued at $356,000. Versant Venture Management LLC acquired a new stake in shares of Contineum Therapeutics during the 2nd quarter worth about $16,169,000. Finally, Johnson & Johnson bought a new stake in Contineum Therapeutics in the 2nd quarter valued at about $34,853,000.
Contineum Therapeutics Company Profile
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
Read More
- Five stocks we like better than Contineum Therapeutics
- How to Read Stock Charts for Beginners
- 3 Stocks That Could Beat the September Blues
- Stock Splits, Do They Really Impact Investors?
- Canopy Growth Stock: Can It Sustain Recent Gains?
- Most active stocks: Dollar volume vs share volume
- Serve Robotics Is Serving Up a Selling Opportunity
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.